FDA Approves Ramucirumab + Erlotinib for First-Line Treatment of Metastatic NSCLC

On May 29, 2020, the U.S. Food and Drug Administration (FDA) approved ramucirumab (CYRAMZA, Eli Lilly and Company) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.

Read full FDA announcement.

Posted 6/2/2020